Biodexa Pharmaceuticals PLC
13F holders, Q2 2024 (June 30)12holders +7
7new positions
0sold out
1famous investor
$0.90avg. 13F price*
At the end of Q2 2024, 12 institutions reported holding Biodexa Pharmaceuticals PLC in their 13F filings, up 7 from Q1 2024. 7 opened new positions and 0 sold out. The largest holders were Virtu Financial LLC ($32K), Citadel Advisors ($30K) and Susquehanna International Group, LLP ($27K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R708
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $120K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 143,745 shares bought and 11,587 shares sold, net +132,158 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Virtu Financial LLC | 0.00% | New | 35,776 | $32K |
| Citadel Advisors | 0.00% | New | 33,441 | $30K |
| Susquehanna International Group, LLP | 0.00% | New | 30,114 | $27K |
| Two Sigma Securities, LLC | 0.00% | New | 20,557 | $18K |
| Ground Swell Capital, LLC | 0.01% | New | 13,078 | $12K |
| UBS Group AG | 0.00% | Add +310.1% | 9,997 | $9K |
| GAMMA Investing LLC | 0.00% | Reduce -65.0% | 3,891 | $3K |
| Rhumbline Advisers | 0.00% | Add +444.2% | 2,710 | $2K |
| Contravisory Investment Management, Inc. | 0.00% | New | 1,000 | $896 |
| Bank of America Corp. | 0.00% | Reduce -83.6% | 859 | $769 |
| Morgan Stanley | 0.00% | No change | 16 | $14 |
| Headlands Technologies LLC | 0.00% | New | 8 | $7 |
"% of holder's portfolio" is BIODEXA PHARMACEUTICALS PLC's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.